Benefit of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia

Gary Schiller, James Gajewski, Myung Lee, Winston Ho, Mary Territo, Richard Champlin

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Despite consolidation and/or maintenance chemotherapy most patients with newly diagnosed acute myelogenous leukemia relapse such that only 20-30% survive free of recurrence at five years. To evaluate the long-term effects of dose-intensive consolidation, we analysed 123 consecutive patients, age 16 to 84 (median 48 years), who received high-dose cytarabine-based consolidation chemotherapy. After a median follow-up of 88 months (range 26 to 126 months), 38 patients remain alive, with 26 in continued remission from 45 to 126+ months. Median remission duration for all eligible patients is 14 months (range 1.3 to 126 months) and actuarial leukemia-free survival at five years is 24 ± 8% Median survival from remission is 24 months (range 1.3 to 126 months) and actuarial survival from remission is 31 ± 9% Eighty-two patients (67% have relapsed with an actuarial risk of relapse of 71 ± 9% at five years. Adverse prognostic factors were age over 45 and male gender. When compared to historical controls (P = 0.02), dose-intensive consolidation produced improved leukemia-free survival for patients age

Original languageEnglish (US)
Pages (from-to)85-90
Number of pages6
JournalLeukemia and Lymphoma
Volume15
Issue number1-2
DOIs
StatePublished - 1994
Externally publishedYes

Fingerprint

Consolidation Chemotherapy
Cytarabine
Acute Myeloid Leukemia
Survival
Recurrence
Leukemia
Maintenance Chemotherapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Benefit of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. / Schiller, Gary; Gajewski, James; Lee, Myung; Ho, Winston; Territo, Mary; Champlin, Richard.

In: Leukemia and Lymphoma, Vol. 15, No. 1-2, 1994, p. 85-90.

Research output: Contribution to journalArticle

Schiller, Gary ; Gajewski, James ; Lee, Myung ; Ho, Winston ; Territo, Mary ; Champlin, Richard. / Benefit of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. In: Leukemia and Lymphoma. 1994 ; Vol. 15, No. 1-2. pp. 85-90.
@article{a7053cd2416d447ca028589b166175a4,
title = "Benefit of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia",
abstract = "Despite consolidation and/or maintenance chemotherapy most patients with newly diagnosed acute myelogenous leukemia relapse such that only 20-30{\%} survive free of recurrence at five years. To evaluate the long-term effects of dose-intensive consolidation, we analysed 123 consecutive patients, age 16 to 84 (median 48 years), who received high-dose cytarabine-based consolidation chemotherapy. After a median follow-up of 88 months (range 26 to 126 months), 38 patients remain alive, with 26 in continued remission from 45 to 126+ months. Median remission duration for all eligible patients is 14 months (range 1.3 to 126 months) and actuarial leukemia-free survival at five years is 24 ± 8{\%} Median survival from remission is 24 months (range 1.3 to 126 months) and actuarial survival from remission is 31 ± 9{\%} Eighty-two patients (67{\%} have relapsed with an actuarial risk of relapse of 71 ± 9{\%} at five years. Adverse prognostic factors were age over 45 and male gender. When compared to historical controls (P = 0.02), dose-intensive consolidation produced improved leukemia-free survival for patients age",
author = "Gary Schiller and James Gajewski and Myung Lee and Winston Ho and Mary Territo and Richard Champlin",
year = "1994",
doi = "10.3109/10428199409051682",
language = "English (US)",
volume = "15",
pages = "85--90",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "1-2",

}

TY - JOUR

T1 - Benefit of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia

AU - Schiller, Gary

AU - Gajewski, James

AU - Lee, Myung

AU - Ho, Winston

AU - Territo, Mary

AU - Champlin, Richard

PY - 1994

Y1 - 1994

N2 - Despite consolidation and/or maintenance chemotherapy most patients with newly diagnosed acute myelogenous leukemia relapse such that only 20-30% survive free of recurrence at five years. To evaluate the long-term effects of dose-intensive consolidation, we analysed 123 consecutive patients, age 16 to 84 (median 48 years), who received high-dose cytarabine-based consolidation chemotherapy. After a median follow-up of 88 months (range 26 to 126 months), 38 patients remain alive, with 26 in continued remission from 45 to 126+ months. Median remission duration for all eligible patients is 14 months (range 1.3 to 126 months) and actuarial leukemia-free survival at five years is 24 ± 8% Median survival from remission is 24 months (range 1.3 to 126 months) and actuarial survival from remission is 31 ± 9% Eighty-two patients (67% have relapsed with an actuarial risk of relapse of 71 ± 9% at five years. Adverse prognostic factors were age over 45 and male gender. When compared to historical controls (P = 0.02), dose-intensive consolidation produced improved leukemia-free survival for patients age

AB - Despite consolidation and/or maintenance chemotherapy most patients with newly diagnosed acute myelogenous leukemia relapse such that only 20-30% survive free of recurrence at five years. To evaluate the long-term effects of dose-intensive consolidation, we analysed 123 consecutive patients, age 16 to 84 (median 48 years), who received high-dose cytarabine-based consolidation chemotherapy. After a median follow-up of 88 months (range 26 to 126 months), 38 patients remain alive, with 26 in continued remission from 45 to 126+ months. Median remission duration for all eligible patients is 14 months (range 1.3 to 126 months) and actuarial leukemia-free survival at five years is 24 ± 8% Median survival from remission is 24 months (range 1.3 to 126 months) and actuarial survival from remission is 31 ± 9% Eighty-two patients (67% have relapsed with an actuarial risk of relapse of 71 ± 9% at five years. Adverse prognostic factors were age over 45 and male gender. When compared to historical controls (P = 0.02), dose-intensive consolidation produced improved leukemia-free survival for patients age

UR - http://www.scopus.com/inward/record.url?scp=0027998875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027998875&partnerID=8YFLogxK

U2 - 10.3109/10428199409051682

DO - 10.3109/10428199409051682

M3 - Article

C2 - 7858506

AN - SCOPUS:0027998875

VL - 15

SP - 85

EP - 90

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1-2

ER -